Amneal Pharmaceuticals posts strong second quarter with 10% revenue growth, raising its full-year 2026 guidance.

Amneal Pharmaceuticals reported second quarter 2026 net revenue of $796 million, up 10% year-over-year, and GAAP diluted EPS of $0.18. The company's adjusted diluted EPS increased 20% to $0.30, beating consensus estimates. Adjusted EBITDA grew 12% to $206 million.

Key Highlights

• The company raised its full-year 2026 guidance, lifting its net revenue forecast to a range of $3.10 billion to $3.20 billion and its Adjusted EBITDA forecast to between $750 million and $780 million.
• Growth was driven by a 17% increase in Specialty net revenue and a 13% rise in Affordable Medicines net revenue, reflecting strong performance from key branded and complex products.
• Adjusted EBITDA increased 12% year-over-year to $206 million, reflecting higher revenue and gross profit.